Company profile
Transcode Therapeutics, Inc.
NASDAQ:RNAZBiotechnology: Pharmaceutical Preparations
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05908773 | — | completed | 2023-04-04 | 2023-08-23 | TransCode Therapeutics | A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid Tumors |
| NCT06260774 | phase1_2 | active_not_recruiting | 2024-09-05 | 2025-09-30 | TransCode Therapeutics | Study of TTX-MC138 in Subjects With Advanced Solid Tumors |
FDA applications (0)
No records yet.